Browsing: Chinese market

Business

Mubadala Invests in UCB’s Neurology and Allergy Division

Abu Dhabi state investor Mubadala and CBC Group have agreed to acquire UCB’s Chinese neurology and allergy business for $680M. This deal, expected to close in Q4 2024 pending regulatory approval, includes UCB’s neurology products (Keppra, Vimpat, Neupro) and allergy medications (Zyrtec, Xyzal), as well as the Zhuhai manufacturing site. UCB confirmed that this transaction will not affect its 2024 forecasts.